GlassScriptPhysician profile
Randy J Yarbrough
NPI 1134197361
$2,154.43
in general payments reported to CMS, 2019-2025
32 companies · $210 in 2025
The $210 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $383 · 2020: $15.25 · 2021: $275 · 2022: $764 · 2023: $339 · 2024: $169 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $718.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $321.19 | 2021-2022 | |
| Grifols USA, LLC | $160.89 | 2021-2022 | |
| Janssen Biotech, INC. | $153.02 | 2022-2023 | Tremfya, Simponi Aria |
| Mallinckrodt Hospital Products INC. | $145.84 | 2022 | |
| Therapeuticsmd, INC. | $145.54 | 2019 | |
| Sumitomo Pharma America, INC. | $138.26 | 2024-2025 | Myfembree, Gemtesa |
| Ucb, INC. | $108.18 | 2022-2023 | Cimzia |
| Astellas Pharma US INC | $97.28 | 2019-2025 | Veozah |
| Boston Scientific Corporation | $93.62 | 2019-2023 | |
| Covidien LP | $85.54 | 2019 | |
| Intuitive Surgical, INC. | $76.62 | 2019 | |
| Abbvie INC. | $70.23 | 2022-2023 | Botox |
| Allergan, INC. | $60.65 | 2019-2021 | |
| Radius Health, INC. | $60.56 | 2022-2024 | Tymlos |
| Pfizer INC. | $49.91 | 2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $39.95 | 2024 | Interstim |
| Minerva Surgical, INC | $34.47 | 2023-2024 | |
| Shield Therapeutics INC | $32.77 | 2025 | |
| Aurinia Pharma U.S., INC. | $28.59 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.69 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.02 | 2022 | |
| Pharmacosmos Therapeutics INC. | $23.64 | 2024 | Monoferric |
| Exeltis, USA INC. | $22.39 | 2023 | Slynd |
| Coloplast Corp | $20.76 | 2024 | |
| Urovant Sciences INC | $19.55 | 2021 | |
| Axonics, INC. | $17.92 | 2023 | Axonics |
| Sobi, INC | $17.86 | 2022 | |
| United Therapeutics Corporation | $17.52 | 2023 | Tyvaso |
| Sage Therapeutics, LLC | $16.16 | 2025 | Zurzuvae |
| Supernus Pharmaceuticals, INC. | $16.16 | 2025 | Qelbree |
| Monaghan Medical Corporation | $15.40 | 2023 | Aerochamber |
| Aspira Women'S Health INC | $15.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randy Yarbrough listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.